RxDoctor Payments DataLook up a doctor →

Boris Furman, DO

Neuromusculoskeletal Medicine & OMM · Manalapan, NJNPI 1164695011

Payments from drug & device makers

$12,002in general payments, 2019–2025

Across 845 payments — averaging $14.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • AbbVie$1K
  • Biogen$1K
  • Novartis$1K
  • Lilly USA, LLC$783
  • Eisai Inc.$601
  • plus $6K from 51 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.86$1,116
AbbVie(2 entities)94$1,107
Biogen64$1,045
Novartis87$1,006
Lilly USA, LLC50$783
Eisai Inc.40$601
Neurocrine Biosciences, Inc.39$599
Kyowa Kirin, Inc.30$542
UCB, Inc.34$469
Pfizer31$444
Johnson & Johnson18$257
SK Life Science, Inc.16$256
Supernus Pharmaceuticals, Inc.15$249
Grifols USA, LLC17$236
Lundbeck LLC15$235
Sumitomo Pharma America, Inc.13$210
Bristol Myers Squibb15$210
Acadia Pharmaceuticals Inc14$199
Amgen12$178
Biohaven Pharmaceutical Holding Company Ltd.19$167
Scilex Pharmaceuticals Inc.11$163
Amneal Pharmaceuticals LLC10$146
Biohaven Pharmaceuticals, Inc.12$137
Avanir Pharmaceuticals, Inc.9$128
Argenx US, Inc.8$127
Averitas Pharma Inc.6$122
Acorda Therapeutics, Inc8$107
AstraZeneca(2 entities)6$103
Catalyst Pharmaceuticals, Inc.6$92
Otsuka America Pharmaceutical, Inc.5$72
Axsome Therapeutics, Inc.4$70
Neurelis, Inc.5$69
MDD US Operations, LLC4$64
Sanofi4$56
Corium, LLC3$49
Octapharma USA, Inc.3$45
Boston Scientific2$43
Adamas Pharmaceuticals, Inc.3$41
Impel Pharmaceuticals Inc.2$39
Tonix Medicines, Inc.2$39
Almatica Pharma LLC3$38
Abbott1$38
Si-bone, Inc.1$33
Indivior Inc.2$32
Vanda Pharmaceuticals Inc.2$31
Alnylam Pharmaceuticals Inc.2$28
SPR Therapeutics, Inc1$25
E.r. Squibb & Sons, L.L.C.2$25
Takeda Pharmaceuticals U.S.A., Inc.1$22
Jazz Pharmaceuticals Inc.1$19
Orexo US, Inc.1$15
Assertio Therapeutics, Inc.1$15
Bausch Health US, LLC1$14
Harmony Biosciences LLC1$14
Collegium Pharmaceutical, Inc.1$12
Vertical Pharmaceuticals, LLC1$11
Impel Pharmaceuticals LLC1$11

How this compares

Too few neuromusculoskeletal medicine & omm providers in New Jerseyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$364,592
Medicare patients
783
Services billed
6,762

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neuromusculoskeletal medicine & omm in Manalapan

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →